Gilead Sciences (GILD)

As the final bells ring on Wall Street for 2025, the biotechnology sector is celebrating a dramatic reversal of fortune. After years of navigating high interest rates and regulatory uncertainty, the industry has closed the year with a powerful rally, fueled by a dovish shift from the Federal Reserve and

As the curtain closes on 2025, the exuberant "risk-on" sentiment that defined the early years of the artificial intelligence boom has been replaced by a somber, calculated retreat. On this final day of the year, December 31, 2025, financial markets are grappling with a stark reality: the American consumer is

March S&P 500 E-Mini futures (ESH26) are down -0.20%, and March Nasdaq 100 E-Mini futures (NQH26) are down -0.32% this morning, pointing to a weak start on Wall Street in the final trading session of 2025.

Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session.

Gilead Sciences (GILD) shows strong technicals and a high-quality setup, suggesting a potential breakout from a tight trading range for chart-focused investors.

According to data released by the U.S. Department of Labor on Wednesday, jobless claims fell by 10,000 to 214,000 in the week ended December 20.

Gilead agreed to acquire Repare's RP-3467 cancer drug for up to $30 million, boosting Repare's cash and expected shareholder payout.

Repare stated that Gilead has agreed to acquire polymerase theta (Polθ) ATPase inhibitor, RP-3467, for a total consideration of $30 million.

Stay updated with the movements of the S&P500 index in the middle of the day on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.

Gilead licensed Assembly Bio's long-acting HSV drugs after Phase 1b data showed antiviral activity and weekly oral dosing potential.

Trump and nine major pharmaceutical companies struck deals to lower drug prices for cash payers and Medicaid, with over $150 billion pledged for U.S. R&D and manufacturing.

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 3.3% in the afternoon session after the stock's positive momentum continued as the company announced a series of positive developments, including successful late-stage trial results for a new HIV treatment, regulatory approval for another HIV drug in the U.K., and a new pricing agreement with the U.S. government. 

The deals expand the pricing program to most targeted drugmakers in exchange for temporary tariff relief.

Dow Jones stock Merck forged a Most Favored Nation agreement with the Trump administration on Friday.

Gilead Sciences (GILD) offers a reliable 2.56% dividend yield, backed by strong profitability, a debt-free balance sheet, and a decade of consistent payouts.

This comes after President Donald Trump urged drugmakers in July to lower drug prices for the U.S. government’s Medicaid program.

The potential agreements would mark another step in Washington’s broader effort to reshape drug pricing.

Gilead said its two-drug bictegravir-lenacapavir tablet was non-inferior to Biktarvy in the Phase 3 ARTISTRY-2 HIV trial.

Arcus Biosciences stock plunged Friday, reversing a nearly 300% gain, after its Gilead-partnered cancer regimen failed.

Gilead Sciences (GILD) presents a strong value investing case, trading at a discount to its industry with high profitability, no debt, and improving earnings growth forecasts.